By Pierre Bertrand
Novartis said the U.S. Food and Drug Administration has approved its drug Cosentyx for the treatment of the hidradenitis suppurativa skin condition.
Novartis said late Tuesday that the approval of the drug is the first of a new biologic treatment option for the condition in nearly a decade.
The regulator’s approval was based on data compiled in the Sunshine and Sunrise Phase 3 study program, Novartis said.
Hidradenitis suppurativa is a chronic and systemic skin disease which causes boil-like bumps that can burst and cause scarring, the company said.
Novartis said there has previously only been one other treatment option for the condition.
Write to Pierre Bertrand at [email protected]
Read the full article here
